section name header

Evidence summaries

Zuclopenthixol Dihydrochloride for Schizophrenia

Oral zuclopenthixol might possibly not differ from other antipsychotics in the treatment of schizophrenia, but the evidence is insufficient. Level of evidence: "D"

A Cochrane review [Abstract] 1 included 20 studies with a total of 1850 subjects with schizophrenia. Data were reported for 12 comparisons, predominantly for the short term (up to 12 weeks) and inpatient populations.

Zuclopenthixol versus:

  1. Placebo:Movement disorders (EPSEs) were similar between groups (RR 6.07 95% CI 0.86 to 43.04; 1 RCT, n = 28). There was no clear difference in numbers leaving the study early (RR 0.29, 95% CI 0.01 to 6.60; 2 RCTs, n = 100).
  2. Chlorpromazine: No clear differences were found for the outcomes of global state (average CGI-SI endpoint score) (MD 0.00, 95% CI -0.49 to 0.49; 1 RCT, n = 60) or movement disorders (EPSEs) (RR 0.94, 95% CI 0.61 to 1.45; 3 RCTs, n = 199). More people left the study early for any reason from the zuclopenthixol group (RR 0.54, 95% CI 0.36 to 0.81; 6 RCTs, n = 766).
  3. Chlorprothixene:There was no clear difference in numbers leaving the study early for any reason (RR 1.00, 95% CI 0.34 to 2.93; 1 RCT, n = 20).
  4. Clozapine:No useable data were presented.
  5. Haloperidol: No clear differences between treatment groups were found for the outcomes global state score (average CGI endpoint score in this and all other comparisons) (MD 0.13, 95% CI -0.30 to 0.55; 1 RCT, n = 49) or leaving the study early (RR 0.99, 95% CI 0.72 to 1.35; 2 RCTs, n = 141).
  6. Perphenazine:Those receiving zuclopenthixol were more likely to require medication in the short term for EPSEs than perphenazine (RR 1.90, 95% CI 1.12 to 3.22; 1 RCT, n = 50). Similar numbers left the study early (RR 0.63, 95% CI 0.27 to 1.47; 2 RCTs, n = 104).
  7. Risperidone:Those receiving zuclopenthixol were more likely to require medications for EPSEs than risperidone (RR 1.92, 95% CI 1.12 to 3.28; 1 RCT, n = 98). There was no clear difference in numbers leaving the study early (RR 1.30, 95% CI 0.84 to 2.02; 3 RCTs, n = 154) or in mental state (average PANSS total endpoint score) (MD -3.20, 95% CI -7.71 to 1.31; 1 RCT, n = 25).
  8. Sulpiride:No clear differences were found for global state (RR 1.18, 95% CI 0.49 to 2.85; 1 RCT, n = 61), requiring hypnotics/sedatives (RR 0.60, 95% CI 0.27 to 1.32; 1 RCT, n = 61) or leaving the study early (RR 2.07 95% CI 0.97 to 4.40; 1 RCT, n = 61).
  9. Thiothixene:No clear differences were found for the outcomes of global state (RR 0.50, 95% CI 0.17 to 1.46; 1 RCT, n = 20) or leaving the study early (RR 0.57, 95% CI 0.24 to 1.35; 1 RCT, n = 20).
  10. Trifluoperazine:No useable data were presented.
  11. Zuclopenthixol depot:There was no clear difference in numbers leaving the study early (RR 1.95, 95% CI 0.36 to 10.58; 1 RCT, n = 46).
  12. Zuclopenthixol dihydrochloride (cis z isomer) versus zuclopenthixol (cis z/trans e isomer):There were no clear differences in reported side-effects ( RR 1.34, 95% CI 0.82 to 2.18; 1 RCT, n = 57) and in numbers leaving the study early (RR 2.15, 95% CI 0.49 to 9.41; 4 RCTs, n = 140).

Comment: The quality of evidence is downgraded by study quality (unclear allocation concealment), imprecise results (limited study size for each comparison) and indirectness (short follow-up time).

References

  • Bryan EJ, Purcell MA, Kumar A. Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database Syst Rev 2017;11():CD005474. [PubMed]

Primary/Secondary Keywords